GeneralTop StoryTop StoryLatest News
India's First Dengue Vaccine Expected in 2027 Amid Concerns
Sentiment: NeutralHigh Priority
What Happened?
India's first dengue vaccine, Takeda's Qdenga, is set for private market release in early 2027. However, clinicians express concerns over its effectiveness against different strains and potential risks.
Key points
- Qdenga is expected to be available in the first half of 2027.
- The vaccine is authorized for individuals aged four to 60.
- Dengue cases in India rose significantly from 44,585 in 2020 to 233,519 in 2024.
- Concerns include the vaccine's effectiveness against different dengue strains and the risk of severe disease.
- The vaccine is tetravalent, targeting all four dengue serotypes.
- Experts emphasize the need for careful evaluation of the vaccine's long-term efficacy.
Key insights
- The vaccine's effectiveness against different strains may vary, impacting its overall success.
- Public awareness and education about the vaccine's benefits and limitations are crucial for its acceptance.
- The ongoing evolution of dengue viruses poses challenges for vaccine efficacy and safety.
Why it matters
The introduction of a dengue vaccine could significantly impact public health in India, where dengue is a growing concern.
Tags
Entities
Takeda· CompanyQdenga· ProductWorld Health Organization· OrganizationDr Reddy’s Laboratories· CompanyDr Sanjeev Bagai· PersonDr Sumit Jain· PersonDr Satish Kumar· Person
Source
India Today
